A highly immunogenic recombinant and truncated protein of the secreted aspartic proteases family (rSap2t) of Candida albicans as a mucosal anticandidal vaccine

FEMS Immunology and Medical Microbiology

Volumn 62, Issue 2, 2011, Pages 215-224

  Sandini, Silvia ^a   La Valle, Roberto ^a   Deaglio, Silvia ^b   Malavasi, Fabio ^b   Cassone, Antonio ^a   De Bernardis, Flavia ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Candida albicans; Mucosal anticandidal vaccine; Sap2

Indexed keywords

ASPARTIC PROTEINASE; ESTRADIOL; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; NICKEL COMPLEX; RECOMBINANT PROTEIN; SECRETED ASPARTYL PROTEINASE 2; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ARTICLE; CANDIDA ALBICANS; FEMALE; FUNGAL STRAIN; NONHUMAN; OVARIECTOMY; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RAT; VAGINA CANDIDIASIS; VAGINA DISCHARGE;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTIBODIES, FUNGAL; ASPARTIC ACID ENDOPEPTIDASES; CANDIDA ALBICANS; CANDIDIASIS, VULVOVAGINAL; CHROMATOGRAPHY, AFFINITY; DISEASE MODELS, ANIMAL; FEMALE; FUNGAL PROTEINS; FUNGAL VACCINES; GENE EXPRESSION; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; RODENT DISEASES; SEQUENCE DELETION; VACCINES, SYNTHETIC; VAGINA;

EID: 79958817918     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2011.00802.x     Document Type: Article

References (42)

1. Ausubel LJ, Krieger JI & Hafler DA (1997) Changes in cytokine secretion induced by altered peptide ligands of myelin basic protein peptide 85-99. J Immunol 159: 2502-2512.
2. Bein M, Schaller M & Korting HC (2002) The secreted aspartic proteinases as a new target in the therapy of candidiasis. Curr Drug Targets 3: 351-357.
3. Boyaka PN, Marinaro M, Vancott JL, Takahashi I, Fujihashi K, Yamamoto M, van Ginkel FW, Jackson RJ, Kiyono H & McGhee JR (1999) Strategies for mucosal vaccine development. Am J Trop Med Hyg 60: 35-45.
4. Bromuro C, La Valle R, Sandini S, Urbani F, Ausiello CM, Morelli L, Fè d'Ostiani C, Romani L & Cassone A (1998) A 70-kDa recombinant heat shock protein of Candida albicans is highly immunogenic and enhances systemic murine candidiasis. Infect Immun 66: 2154-2162.
5. Cassone A (2008) Fungal vaccine: real progress from real challenges. Lancet Infect Dis 8: 114-124.
6. Cassone A, Boccanera M, Adriani D, Santoni G & De Bernardis F (1995) Rat clearing a vaginal infection by Candida albicans acquired specific antibody-mediated resistance to vaginal reinfection. Infect Immun 63: 2619-2625.
7. Cassone A, De Bernardis F & Torosantucci A (2005) An outline of the role of anti-Candida antibodies within the context of passive immunization and protection from candidiasis. Curr Mol Med 5: 377-382.
8. Cassone A, De Bernardis F & Santoni G (2007) Anticandidal immunity and vaginitis: novel chances for immune intervention. Infect Immun 75: 4675-4686.
9. Cutler JE (2005) Defining criteria for anti-mannan antibodies to protect against candidiasis. Curr Mol Med 5: 383-392.
10. Cutler JE, Deepe GS & Klein BS (2007) Advances in combating fungal diseases: vaccines on the threshold. Nat Rev Microbiol 5: 13-28.
11. Dan MJ & Levitz SM (2006) Prospects for development of vaccines against fungal diseases. Drug Resist Update 9: 105-110.
12. De Bernardis F & Boccanera M (2002) Mucosal infection and immunity in candidiasis. Fungal Pathogenesis: Principles and Clinical Applications (Calderone R & Chilar R, eds), pp. 461-482. Marcell Dekker Inc, New York, NY.
13. De Bernardis F, Boccanera M, Adriani D, Spreghini E, Santoni G & Cassone A (1997) Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect Immun 68: 3297-3304.
14. De Bernardis F, Lorenzini R & Cassone A (1999) Rat model of Candida vaginal infection. Handbook of Animal Models of Infection (Otozak & Sande Merle A, eds), pp. 735-740. Academic Press, New York, NY.
15. De Bernardis F, Santoni G, Boccanera M, Spreghini E, Adriani D, Morelli L & Cassone A (2000) Local anticandidal immune responses in a rat model of vaginal infection by and protection against Candida albicans. Infect Immun 68: 3297-3304.
16. De Bernardis F, Sullivan PA & Cassone A (2001) Aspartyl proteinases of Candida albicans and their role in pathogenicity. Med Mycol 39: 303-313.
17. De Bernardis F, Boccanera M, Adriani D, Girolamo A & Cassone A (2002) Intravaginal and intranasal immunizations are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis. Infect Immun 70: 2725-2729.
18. De Bernardis F, Liu H, O'Mahony R et al. (2007) Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis. J Infect Dis 195: 149-157.
19. De Bernardis F, Santoni G, Boccanera M, Lucciarini R, Arancia S, Sandini S, Amantini C & Cassone A (2010) Protection against rat vaginal Candidiasis by adoptive transfer of vaginal B lymphocytes. FEMS Yeast Res 10: 432-440.
20. Elson CO (1989) Cholera toxin and its subunits as potential as potential oral adjuvants. Immunol Today 146: 29-33.
21. Elson CO (1996) Cholera toxin as mucosal adjuvant. Mucosal Vaccines (Kiyono H, Ogra PL & McGhee JR, eds), pp. 59-72. Academic Press Inc, San Diego, CA.
22. Hochuli E, Banwarth W, Dobli H, Gentz R & Stuber D (1988) Genetic approach to facilitate purification of recombinant proteins with a novel metal-chelate absorbant. Bio/Technology 6: 1321-1325.
23. Horenstein AL, Crivellin F, Funaro A, Said M & Malavasi F (2003) Design and scale-up of downstream processing of monoclonal antibodies for cancer therapy: from research to clinical proof of principle. J Immunol Methods 275: 99-112.
24. La Valle R, Sandini S, Gomez MJ, Mondello F, Romagnoli G, Nisini R & Cassone A (2000) Generation of recombinant 65-kDa mannoprotein (MP65), a major antigen target of cell-mediated immune response to Candida albicans. Infect Immun 68: 6777-6784.
25. Malavasi F, Caligaris-Cappio F, Milanese C, Dellabona P, Richiardi P & Carbonara AO (1984) Characterization of a murine monoclonal antibody specific for human early lymphohemopoietic cells. Hum Immunol 9: 9-20.
26. Martins MD, Lozano-Chiu M & Rex JH (1998) Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Infect Dis 27: 1291-1294.
27. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD & Warnock DW (2001) Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 33: 641-647.
28. Naglik JR, Challacombe SJ & Hube B (2003) Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol R 67: 400-428.
29. Naglik JR, Moyes D, Makwana J et al. (2008) Quantitative expression of the Candida albicans secreted aspartyl proteinase gene family in human oral and vaginal candidiasis. Microbiology 154: 3266-3280.
30. Nisini R, Romagnoli G, Gomez MJ, La Valle R, Mariotti S, Teloni R & Cassone A (2001) Antigenic properties and processing requirements of 65-kilodalton mannoprotein, a major antigen target of anti-Candida human T-cell response, as disclosed by specific human T-cell clones. Infect Immun 69: 3728-3736.
31. Nucci M & Marr KA (2005) Emerging fungal diseases. Clin Infect Dis 41: 521-526.
32. Perbal B (1988) A Practical Guide to Molecular Cloning. Wiley-Interscience Publications, New York, NY.
33. Pfaller MA & Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20: 133-163.
34. Powderly WG, Mayer KH & Perfect JR (1999) Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment. AIDS Res Hum Retrov 15: 1405-1412.
35. Ross IK, De Bernardis F, Emerson GW, Cassone A & Sullivan PA (1990) The secreted aspartate proteinase of Candida albicans: physiology of secretion and virulence of a proteinase-deficient mutant. J Gen Microbiol 136: 687-694.
36. Sandini S, Melchionna R, Arancia S, Gomez MJ & La Valle R (1999) Generation of a highly immunogenic recombinant enolase of the human opportunistic pathogen Candida albicans. Biotechnol Appl Bioc 29: 223-227.
37. Sandini S, La Valle R, De Bernardis F, Macrì C & Cassone A (2007) The 65-kilodalton mannoprotein gene of Candida albicans encodes a putative β-glucanase adhesin required for hyphal morphogenesis and experimental pathogenicity. Cell Microbiol 9: 1223-1238.
38. Santoni G, Boccanera M, Adriani D, Lucciarini R, Amantini C, Cassone A & De Bernardis F (2002) Immune-mediated protection against vaginal candidiasis: evidence for a major role of vaginal CD4+T cells and possible participation of other local lymphocyte effectors. Infect Immun 70: 4791-4797.
39. Stringaro A, Crateri P, Pellegrini G, Arancia G, Cassone A & De Bernardis F (1997) Ultrastructural localization of the secretory aspartyl proteinase in Candida albicans cell wall in vitro and in experimentally infected rat vagina. Mycopathologia 137: 95-107.
40. Stuber D, Matile H & Garotta G (1990) System for high-level production in E. coli and rapid purification of recombinant proteins:application to epitope mapping preparation of antibodies and structure/function analysis. Immunological Methods (Lefkovitz I & Pernis B, eds), pp. 122-151. Academic Press Inc, Orlando, FL.
41. Trabocchi A, Mannino C, Machetti F, De Bernardis S, Cauda R, Cassone A & Guarna A (2010) Identification of inhibitors of pharmacoresistant Candida albicans strains from a library of bicyclic peptidomimetic compounds. J Med Chem 53: 2502-2509.
42. Vilanova M, Teixeira L, Caramalho I, Torrado E, Marques A, Madureira P, Ribeiro A, Ferreira P, Gama M & Demengeot J (2004) Protection against systemic candidiasis in mice immunized with secreted aspartic proteinase 2. Immunity 111: 334-342.